Early results from an ongoing Phase 2 trial (NCT07222579) show that a subcutaneous (under-the-skin) form of blinatumomab (Blincyto) may be highly effective and well tolerated for mixed phenotype acute leukemia (MPAL), a rare and aggressive blood cancer. The first patient treated, a 77-year-old with Philadelphia chromosome–negative MPAL, achieved a complete response after just one 26-day […]
New results from the KEYMAKER-U03 substudy 03A (2026) show that several three-drug immunotherapy combinations work well as first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). The study compared the current standard treatment—pembrolizumab plus lenvatinib—with four new triplet regimens. The standard therapy had an overall response rate (ORR) of 80.6%. Adding belzutifan resulted in
New study shows that Orca-T, a high-precision donor cell therapy, can be reliably manufactured and delivered at scale. Orca-T is an investigational alternative to traditional bone marrow transplants for blood cancers such as AML, ALL, and MDS. It uses a carefully selected mix of donor immune cells to lower the risk of graft-versus-host disease (GVHD). In an
Orca-T Manufacturing Data Support Scalable Precision Transplant With Lower GVHD Rates Read More »
A new article demonstrates how FES-PET/CT is becoming an important imaging tool for estrogen receptor (ER)–positive breast cancer, especially invasive lobular carcinoma (ILC), which is often hard to detect with standard scans. ILC grows in thin “single-file” lines instead of forming clear lumps. Because of this pattern, it can be difficult to see on mammograms, ultrasound, and
A recent study examined eye side effects from mirvetuximab soravtansine-gynx (Elahere), a drug approved by the U.S. Food and Drug Administration in 2024 for platinum-resistant ovarian cancer. Eye problems usually appeared early, about five weeks after starting treatment, and most were mild to moderate, including corneal damage and blurred vision. However, researchers found an unexpected
The SWOG S1512 Phase 2 trial studied giving pembrolizumab (Keytruda) before surgery to patients with resectable desmoplastic melanoma, a rare type of skin cancer usually found on sun-exposed areas. After just three doses of pembrolizumab, 71% of patients had no cancer left in their surgical tissue samples. At three years, 74% of patients had no
Pre-Surgery Keytruda Shows Strong Results in Rare Desmoplastic Melanoma Study Read More »
Treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are moving from traditional chemoimmunotherapy (CIT) to targeted drugs. The BRUIN CLL-313 Phase III study tested pirtobrutinib, a new noncovalent Bruton tyrosine kinase inhibitor (ncBTKi), in patients who had never received treatment before. The study compared pirtobrutinib alone to bendamustine plus rituximab (BendaR), a
BRUIN CLL-313 Study: Pirtobrutinib Outperforms Chemoimmunotherapy in Frontline CLL Read More »
Accurate T staging in early gastric cancer (EGC) is critical because it determines treatment. Tumors limited to the mucosa (T1a) can often be treated with minimally invasive endoscopic procedures, while deeper tumors (T1b) usually require major surgery. A new study found that EUS had an overall accuracy of about 75%. It was very good at
Study Shows Endoscopic Ultrasound Helps Guide Treatment in Early Gastric Cancer Read More »
Colorectal cancer (CRC) is a major cause of death worldwide, and early-onset cases in people under 50 have risen sharply in Western countries. Although early detection can often cure the disease, common blood markers like CEA are not specific enough for reliable screening. In a recent study, researchers tested a new approach called Thermal Liquid
Hybrid Thermal Liquid Biopsy Model Improves Accuracy of Colorectal Cancer Detection Read More »
Researchers are shifting toward blood-based biomarker tests to detect colorectal adenomas (CRAs), which are precancerous lesions that can lead to colorectal cancer. While colonoscopy and stool tests (FIT) are standard, blood tests are more convenient and may better detect non-bleeding lesions, improving patient compliance. Key approaches include noncoding RNAs (such as microRNAs and circular RNAs),
Blood-Based Biomarkers Show Promise for Early Detection of Colorectal Adenomas Read More »